AC
KYMR icon

Aaron Cowen’s Kymera Therapeutics KYMR Stock Holding History

Aaron Cowen’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-275,000
Closed -$12M – 101
2025
Q2 		$12M Buy
+275,000
New +$9.47M 0.36% 53
2020
Q4 		– Sell
-110,230
Closed -$3.56M – 116
2020
Q3 		$3.56M Buy
+110,230
New +$3.36M 0.06% 72

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Aaron Cowen's KYMR Position: Q3 2025 in Review

Aaron Cowen sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 275,000 shares — an estimated $12M sold.

Aaron Cowen first reported a position in KYMR in Q3 2020 and held it in 2 quarters. The position peaked at $12M in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Aaron Cowen reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Aaron Cowen sold 275,000 Kymera Therapeutics shares in Q3 2025, an estimated $12M.
  • Aaron Cowen first reported a position in Kymera Therapeutics in Q3 2020 and held it in 2 quarters.
  • Aaron Cowen's Kymera Therapeutics position peaked at $12M in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Suvretta Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.